After a day hiking in the forest, the last thing a person wants to discover is a tick burrowing into their skin.
Days after plucking off the bloodsucking insect, the hiker might develop a rash resembling a bull’s-eye, a tell-tale sign of Lyme disease. Yet not everybody who contracts Lyme disease gets the rash. Now, researchers reporting in ACS Nano have devised a blood test that quickly and sensitively diagnoses the disease at early stages.
About 300,000 cases of Lyme disease, which is caused by the tick-borne bacteria Borrelia burgdorferi, are diagnosed in the U.S. each year, according to the U.S. Centers for Disease Control and Prevention. Early symptoms of the disease include the characteristic skin rash, along with fever, headache, chills and muscle aches. If not treated promptly with antibiotics, more severe symptoms, such as facial palsy, nerve pain, heart palpitations and arthritis, can occur. However, 10–20% of infected people do not develop the rash, and existing diagnostic blood tests are slow, costly or insensitive at early stages, when treatment is most effective. Aydogan Ozcan and colleagues at UCLA wanted to develop a fast, easy-to-use and inexpensive blood test to diagnose Lyme disease soon after infection.
The researchers built a handheld, paper-based device to detect antibodies against the B. burgdorferi bacteria in serum samples. The device included a sensing membrane that contained several spots covering seven bacterial antigens and a synthetic peptide. Antibodies from serum samples that attached to the spots were detected with a solution that changed color, depending on the amount of antibody captured. The researchers took pictures of the color changes on a smart phone, then analyzed all of the spots with a neural network they developed that could determine whether the sample was positive or negative for Lyme disease. When tested on 50 blood samples from people with or without early-stage Lyme disease, the assay had a specificity of 96.3% and a sensitivity of 85.7%. In addition to being much more sensitive than existing tests, the assay requires 15 minutes to complete and costs only 42 cents per test.
Learn more: Paper-based test could diagnose Lyme disease at early stages
Go deeper with Bing News on:
Lyme disease
- Probability of developing Lyme disease is genetically influenced, research suggests
Lyme disease is the most common disease transmitted by tick bites in Germany. Whether a particular genetic predisposition plays a role in the development of the disease and which immunological processes in the body are involved is not yet sufficiently understood.
- 5 Signs of Lyme Disease You Really Shouldn’t Ignore
Lyme disease is a very, very antibiotic-responsive condition. It has a bad reputation for being difficult to treat, but it’s never too late to treat it,” Anne Bass, MD, a rheumatologist at the Hospital for Special Surgery in New York City,
Go deeper with Google Headlines on:
Lyme disease
[google_news title=”” keyword=”Lyme disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Lyme disease test
- MAY IS LYME AND TICK-BORNE DISEASE AWARENESS MONTH
Lyme and other Tick-Borne Disease, transmitted through the bite of an infected tick, are endemic throughout St. Lawrence County and are a nationally recognized health concern. Individuals are at risk ...
- Maine CDC marks Lyme Disease Awareness Month
The Maine Center for Disease Control and Prevention urges Maine residents and visitors to take precautions to make tick prevention a “big deal” this month. Gov. Janet Mills has again proclaimed May ...
- Probability of developing Lyme disease is genetically influenced, research suggests
Lyme disease is the most common disease transmitted by tick bites in Germany. Whether a particular genetic predisposition plays a role in the development of the disease and which immunological ...
- Dog owners warned against Lyme disease as nice weather returns
Lameness: This comes from inflammation of the joints, which is also one of the most recognised signs that your dog has Lyme disease. Lameness can come and go, but also shift from one leg to another.
- Flightpath Biosciences Begins Human Clinical Testing of the World’s First Narrow-Spectrum Antibiotic Targeting Lyme Disease
Lyme disease is the fastest-growing vector-borne illness in the U.S., with an estimated 476,000 new cases every year. Today, generic, broad-spectrum antibiotics are the standard-of-care for treating ...
Go deeper with Google Headlines on:
Lyme disease test
[google_news title=”” keyword=”Lyme disease test” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]